{"transactions":[{"id":4616448,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":35190,"kind":"person","name":"Miralles Gines Diego","position":1,"cik":"0001773413","reported_name":"Miralles Gines Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Head of R&D"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-09-11T22:37:47.000Z","date":"2026-09-09","kind":"grant","planned":false,"acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period."}],"balance_after":135000,"derivative":{"exercise_price":10.79,"expiration_date":"2036-09-08","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001193125-26-389514","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526389514/ownership.xml","form_type":"4"}},{"id":4616447,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":35190,"kind":"person","name":"Miralles Gines Diego","position":1,"cik":"0001773413","reported_name":"Miralles Gines Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Head of R&D"}}],"security":"Common Stock","published_at":"2026-09-11T22:37:47.000Z","date":"2026-09-09","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2024 Equity Incentive Plan."}],"balance_after":122500,"source":{"system":"sec-edgar","filing":"0001193125-26-389514","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526389514/ownership.xml","form_type":"4"}},{"id":725615,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35190,"kind":"person","name":"Miralles Gines Diego","position":1,"cik":"0001773413","reported_name":"Miralles Gines Diego","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T21:46:26.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":19000,"derivative":{"exercise_price":14.19,"expiration_date":"2036-06-25","underlying":"Class A Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001628280-26-045845","document":"wk-form4_1782510384.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000162828026045845/wk-form4_1782510384.xml","form_type":"4"}},{"id":772226,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":35190,"kind":"person","name":"Miralles Gines Diego","position":1,"cik":"0001773413","reported_name":"Miralles Gines Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Head of R&D"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-05-19T12:11:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":232500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents stock option award granted under the Issuer's 2025 Inducement Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares initially subject to the option will vest and become exercisable on May 15, 2027, and the balance of the shares subject to the option shall vest and become exercisable at a rate of 1/36th per month over the following 36 months."}],"balance_after":232500,"derivative":{"exercise_price":9.22,"expiration_date":"2036-05-17","underlying":"Common Stock","underlying_shares":232500},"source":{"system":"sec-edgar","filing":"0001193125-26-229727","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526229727/ownership.xml","form_type":"4"}},{"id":772225,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":35190,"kind":"person","name":"Miralles Gines Diego","position":1,"cik":"0001773413","reported_name":"Miralles Gines Diego","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & Head of R&D"}}],"security":"Common Stock","published_at":"2026-05-19T12:11:07.000Z","date":"2026-05-18","kind":"grant","planned":false,"acquired":true,"shares":77500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit award granted under the Issuer's 2025 Inducement Plan."}],"balance_after":77500,"source":{"system":"sec-edgar","filing":"0001193125-26-229727","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526229727/ownership.xml","form_type":"4"}},{"id":1101134,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35190,"kind":"person","name":"Miralles Gines Diego","position":1,"cik":"0001773413","reported_name":"Miralles Gines Diego","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-06-26T21:39:45.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":14750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2026, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":14750,"derivative":{"exercise_price":4.01,"expiration_date":"2035-06-25","underlying":"Class A Common Stock","underlying_shares":14750},"source":{"system":"sec-edgar","filing":"0001437749-25-021365","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925021365/rdgdoc.xml","form_type":"4"}},{"id":1101122,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":35190,"kind":"person","name":"Miralles Gines Diego","position":1,"cik":"0001773413","reported_name":"Miralles Gines Diego","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-06-26T20:30:12.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":13750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of  June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting."}],"balance_after":13750,"derivative":{"exercise_price":1.61,"expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":13750},"source":{"system":"sec-edgar","filing":"0001415889-25-018276","document":"form4-06262025_040604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817241/000141588925018276/form4-06262025_040604.xml","form_type":"4"}},{"id":1203998,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":35190,"kind":"person","name":"Miralles Gines Diego","position":1,"cik":"0001773413","reported_name":"Miralles Gines Diego","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-03-17T20:12:41.000Z","date":"2025-03-14","kind":"grant","planned":false,"acquired":true,"shares":29500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan, pursuant to the Issuer's Non-Employee Director Compensation Program, as amended. One-third of the option shares vest on March 14, 2026, and the remainder vests in 24 equal monthly installments thereafter, subject to the Reporting Person's continuous service."}],"balance_after":29500,"derivative":{"exercise_price":6.67,"expiration_date":"2035-03-13","underlying":"Class A Common Stock","underlying_shares":29500},"source":{"system":"sec-edgar","filing":"0001437749-25-008003","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855175/000143774925008003/rdgdoc.xml","form_type":"4"}},{"id":3033383,"issuer":{"id":109568,"kind":"organization","name":"NeuBase Therapeutics, Inc.","symbol":"NBSE"},"owners":[{"id":35190,"kind":"person","name":"Miralles Gines Diego","position":1,"cik":"0001773413","reported_name":"Miralles Gines Diego","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2020-09-11T17:20:35.000Z","date":"2020-09-09","kind":"grant","acquired":true,"shares":14634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total shares shall vest on the first anniversary of September 9, 2020, and the remaining shares shall vest on an equal monthly basis over the following 36 months."}],"balance_after":14634,"derivative":{"exercise_price":8.8,"expiration_date":"2030-09-09","underlying":"Common Stock","underlying_shares":14634},"source":{"system":"sec-edgar","filing":"0001104659-20-104491","document":"tm2030658d3_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1173281/000110465920104491/tm2030658d3_4.xml","form_type":"4"}},{"id":3460982,"issuer":{"id":109568,"kind":"organization","name":"NeuBase Therapeutics, Inc.","symbol":"NBSE"},"owners":[{"id":35190,"kind":"person","name":"Miralles Gines Diego","position":1,"cik":"0001773413","reported_name":"Miralles Gines Diego","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2019-07-16T20:34:21.000Z","date":"2019-07-12","kind":"grant","acquired":true,"shares":227330,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the total shares subject to the option shall vest monthly over three years."}],"balance_after":227330,"derivative":{"exercise_price":5.39,"expiration_date":"2029-07-12","underlying":"Common stock","underlying_shares":227330},"source":{"system":"sec-edgar","filing":"0001387131-19-005130","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1173281/000138713119005130/ownership.xml","form_type":"4"}}]}